NOW: TrumpRx Expanding

Prescription pad with various colorful pills and a stethoscope — TRUMPRX BOMBSHELL EXPANSION

AbbVie and Genentech just agreed to slash sky-high drug list prices for uninsured Americans through the White House’s TrumpRx program—putting pressure on an industry long accused of pricing patients out of care.

Story Snapshot

AbbVie and Genentech are set to become the 10th and 11th drugmakers to launch offerings on the TrumpRx discount program on April 8, 2026.
AbbVie’s Humira is listed at about $950 via TrumpRx coupons, down from more than $6,900 (an 86% reduction reported by multiple outlets).
Genentech’s flu drug Xofluza is listed at about $50, down from $168 (about a 70% reduction).
The TrumpRx site expanded from roughly 40 discounted medications in February 2026 to more than 61 medications within two months.

AbbVie and Genentech Join as TrumpRx Expands

AbbVie and Genentech officially launch on TrumpRx on April 8, 2026, marking another step in the administration’s push to reduce out-of-pocket prescription costs for people without insurance.

Reporting indicates the White House negotiated company-by-company arrangements before the public rollout, including a deal with Genentech announced in December 2025 and an AbbVie agreement in January 2026. The announcement highlights growth in participation, not a single sweeping federal price mandate.

CBS News Exclusive: Drug-making giants Abbvie and Genentech will start selling medications at a discount soon on TrumpRx. https://t.co/vo4KCd2bkX

— CBS News (@CBSNews) April 6, 2026

TrumpRx’s most immediate significance is who it targets: uninsured patients and patients whose insurance does not cover a specific drug, who would otherwise face the full list price.

That distinction matters in a system where insured patients often benefit from negotiated rates, rebates, and formularies that are largely invisible to the public. For uninsured families, the “sticker price” is real, and it can make routine treatment financially impossible.

Humira and Xofluza Discounts Put List Prices in the Spotlight

AbbVie’s headline offering is Humira (adalimumab), a widely used treatment for conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

Coverage reports indicate the TrumpRx price is about $950, compared with a list price of over $6,900. Genentech’s highlighted offering is Xofluza, a flu treatment, priced at around $50 compared with $168.

Those drops do not resolve every access barrier, but they sharply illustrate the gap between list prices and what many Americans can pay.

Amgen also expanded its TrumpRx lineup alongside the AbbVie and Genentech launch, adding medications such as Enbrel for arthritis and Otezla for plaque psoriasis, according to published reports.

The broader list growth—from about 40 drugs at launch in February 2026 to more than 61—suggests the program is moving quickly through negotiated additions rather than waiting on lengthy rulemaking. What remains unclear in available reporting is how many patients are using the program and how consistently pharmacies process the coupons.

Why Both Parties Are Watching: Affordability vs. Government Reach

TrumpRx presents a familiar trade-off: lowering costs for citizens who are most exposed to inflated list prices while avoiding a blanket expansion of federal control over health care.

The program appears structured as a targeted discount platform rather than a new entitlement, which may appeal to voters wary of permanent spending commitments.

At the same time, direct White House involvement in pricing negotiations will raise questions about how far executive power should go in markets.

From a left-of-center perspective, the discounts reinforce a long-running critique that drug pricing lacks transparency and can punish the uninsured.

Democrats are likely to argue this should lead to more aggressive federal action, while Republicans will emphasize results achieved through negotiated participation and public pressure rather than heavy regulatory command-and-control.

The reporting provided does not include outside expert analysis or long-term sustainability projections, leaving open debates about scale, enforcement, and whether more manufacturers will join.

The Deeper Frustration: A System Built for Insiders

TrumpRx’s rapid expansion taps into a broader bipartisan frustration: many Americans believe powerful institutions respond only when forced by politics, publicity, or crisis.

When a single drug’s list price can exceed what most families earn in months, citizens conclude the system is calibrated for insiders, not patients.

The available reporting does not show how the discounts affect manufacturer revenues or broader premiums, but the visibility of these price comparisons is likely to intensify demands for accountability across the supply chain.

For now, the concrete takeaway is narrow but meaningful: uninsured patients who need specific high-cost drugs may have a new, lower-priced option starting April 8.

The open questions are the ones voters increasingly focus on—who qualifies, how easily people can use it, and whether Washington can deliver durable, transparent savings without building another bureaucratic maze. Until utilization data is reported, the program’s real-world impact will be measured one patient at a time.